Gilead's antibiotic Cayston denied EU marketing endorsement
This article was originally published in Scrip
Executive Summary
The EU's CHMP has adopted a negative opinion of Gilead's inhaled antibiotic Cayston (aztreonam lysine) for the treatment of chronic airway infections caused by Pseudomonas aeruginosa in adults with cystic fibrosis because the committee was not convinced that the drug's benefits outweighed its risks.